invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.
Company profile
Ticker
NVTAQ
Exchange
Website
CEO
Sean Emerson George
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Locus Development Inc
SEC CIK
Corporate docs
Subsidiaries
ArcherDX, LLC • ArcherDX Clinical Services, Inc. • Ciitizen, LLC • Genelex India Private Limited • Genetic Solutions LLC • Genosity, LLC • Good Start Genetics, Inc. • Invitae Australia PTY LTD • Invitae Canada Inc. • Invitae Israel Inc Ltd. ...
NVTAQ stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
4 Apr 24
8-K
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
6 Mar 24
25-NSE
Exchange delisting
21 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Feb 24
8-K/A
Cost Associated with Exit or Disposal Activities
24 Jan 24
8-K
Invitae Completes Sale of Reproductive Health Assets to Natera
22 Jan 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K/A
Cost Associated with Exit or Disposal Activities
11 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
14 Dec 23
Transcripts
NVTAQ
Earnings call transcript
2023 Q3
8 Nov 23
NVTAQ
Earnings call transcript
2023 Q2
8 Aug 23
NVTAQ
Earnings call transcript
2023 Q1
9 May 23
NVTAQ
Earnings call transcript
2022 Q4
28 Feb 23
NVTAQ
Earnings call transcript
2022 Q3
8 Nov 22
NVTAQ
Earnings call transcript
2022 Q2
10 Aug 22
NVTAQ
Earnings call transcript
2022 Q1
4 May 22
NVTAQ
Earnings call transcript
2021 Q4
25 Feb 22
NVTAQ
Earnings call transcript
2021 Q3
9 Nov 21
NVTAQ
Earnings call transcript
2021 Q2
4 Aug 21
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Nikko Asset Management Americas, Inc.
13 Feb 24
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
5 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
29 Jan 24
4
Robert L Nussbaum
21 Dec 23
4
Thomas Brida
21 Dec 23
4
David Sholehvar
14 Nov 23
3
David Sholehvar
14 Nov 23
4
Thomas Brida
20 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 168.11 mm | 168.11 mm | 168.11 mm | 168.11 mm | 168.11 mm | 168.11 mm |
Cash burn (monthly) | 21.72 mm | 4.91 mm | 326.73 mm | 125.41 mm | 22.30 mm | 19.86 mm |
Cash used (since last report) | 144.50 mm | 32.68 mm | 2.17 bn | 834.39 mm | 148.35 mm | 132.10 mm |
Cash remaining | 23.60 mm | 135.42 mm | -2.01 bn | -666.28 mm | 19.75 mm | 36.01 mm |
Runway (months of cash) | 1.1 | 27.6 | -6.1 | -5.3 | 0.9 | 1.8 |
Institutional ownership, Q4 2023
72.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 152 |
Opened positions | 17 |
Closed positions | 83 |
Increased positions | 35 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 69.95 bn |
Total shares | 208.52 mm |
Total puts | 450.40 k |
Total calls | 124.30 k |
Total put/call ratio | 3.6 |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 93.06 mm | $98.65 mm |
ARK Investment Management | 32.55 mm | $20.40 bn |
CMTDF Sumitomo Mitsui Trust | 16.76 mm | $10.51 bn |
Nikko Asset Management Americas | 16.76 mm | $10.56 bn |
Vanguard | 14.66 mm | $9.19 bn |
STT State Street | 6.18 mm | $3.87 bn |
NTRS Northern Trust | 2.31 mm | $1.45 bn |
Renaissance Technologies | 2.20 mm | $1.38 mm |
Charles Schwab Investment Management | 2.13 mm | $1.34 bn |
Baker Bros. Advisors | 1.76 mm | $1.11 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Dec 23 | Brida Thomas | Common Stock | Payment of exercise | Dispose F | No | No | 0.648 | 17,404 | 11.28 k | 916,183 |
20 Dec 23 | Nussbaum Robert L | Common Stock | Payment of exercise | Dispose F | No | No | 0.648 | 17,404 | 11.28 k | 551,941 |
13 Nov 23 | David Sholehvar | Common Stock | Grant | Acquire A | No | No | 0 | 850,000 | 0.00 | 850,000 |
18 Oct 23 | Brida Thomas | Common Stock | Grant | Acquire A | No | No | 0 | 229,500 | 0.00 | 933,587 |
News
Softbank-Backed Cohesity To Acquire Veritas Data Security Unit For $3B: Report
8 Feb 24
US Stocks Gain; Uber Posts Upbeat Sales
7 Feb 24
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
5 Feb 24
12 Health Care Stocks Moving In Monday's Intraday Session
5 Feb 24
'Invitae Hires FTI, Kirkland & Ellis To Advise Options To Address $1.5B Of Debt As Company Prepares For Bankruptcy; Co Has Been Selling Assets To Shore Up Liquidity As Business Tanks' - WSJ
5 Feb 24
Press releases
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
13 Feb 24
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
30 Jan 24
Natera Acquires Reproductive Health Assets from Invitae
22 Jan 24
Invitae Completes Sale of Reproductive Health Assets to Natera
22 Jan 24